TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26192398

Group type: EXPERIMENTAL
Intervention: High-frequency oscillation (HFO)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Conventional ventilation (CV)
Number of subjects: 546

Group type: COMPARATOR
Intervention: ENE status (nonenrollment)
Number of subjects: 546
Study: 23277434

Group type: EXPERIMENTAL
Intervention: EVLWI-T measurement
Number of subjects: 60

Group type: COMPARATOR
Intervention: Norepinephrine administration
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pulmonary capillary wedge pressures
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unsuitability for transplantation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transplant survival
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gravimetric analysis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Correlation between EVLW-T and EVLW-G
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cytokine levels in BAL fluid
Number of subjects: 60
Study: 16998740

Group type: EXPERIMENTAL
Intervention: Dobutamine Stress Echocardiography (DSE) with echo-contrast (Optisone) at 0-40 microg/kg
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: DSE
Number of subjects: 69
Study: 12709088

Group type: EXPERIMENTAL
Intervention: Thiazide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alkaline citrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General or specific dietary and drinking advice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological therapy
Number of subjects: 0
Study: 9915315

Group type: EXPERIMENTAL
Intervention: Milrinone (30 microg/kg bolus administered progressively in 10 min, followed by a continuous infusion of 0.5 microg x kg(‐1) x min(‐1))
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 22
Study: 7675954

Group type: EXPERIMENTAL
Intervention: 8.33 mg phenylpropanolamine gum
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 107
Study: 1665178

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg and Hydrochlorothiazide 12.5 mg once daily (L/HCTZ)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Captopril 50 mg and Hydrochlorothiazide 25 mg once daily (C/HCTZ)
Number of subjects: 174
Study: 7235321

Group type: EXPERIMENTAL
Intervention: Metaproterenol metered dose aerosol (1.5 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31493958

Group type: EXPERIMENTAL
Intervention: Verbal statements of empathy
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Nonverbal actions of empathy
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Context of medical appointment
Number of subjects: 466
Study: 29902175

Group type: EXPERIMENTAL
Intervention: PA Barriers subscales
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: PA Outcome Expectancies subscales
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: PA Home Environment subscale on support for PA
Number of subjects: 641
Study: 28807986

Group type: EXPERIMENTAL
Intervention: Turbine-driven ventilator
Number of subjects: 24

Group type: COMPARATOR
Intervention: Self-inflating bag
Number of subjects: 24
Study: 25056444

Group type: EXPERIMENTAL
Intervention: Placebo expectation group (told the cream would reduce pain)
Number of subjects: 134

Group type: COMPARATOR
Intervention: No-expectation group (told the cream was a hand cleanser)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Participants with prior experience with pain from cold water immersion
Number of subjects: 134
Study: 23436265

Group type: EXPERIMENTAL
Intervention: etravirine 200 mg bid for 8 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir 400/100 mg bid for 16 days with etravirine 200 mg bid on days 9-16
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Coadministration of etravirine and lopinavir/ritonavir
Number of subjects: 16
Study: 21045816

Group type: EXPERIMENTAL
Intervention: EST followed by large balloon dilation (LBD)
Number of subjects: 90

Group type: COMPARATOR
Intervention: EST followed by mechanical lithotripsy (ML)
Number of subjects: 90
Study: 18328834

Group type: EXPERIMENTAL
Intervention: Troponin T
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Creatine Kinase (CK)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Creatine Kinase-MB (CK-MB)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Single-photon emission computed tomography (SPECT)
Number of subjects: 267
Study: 15733631

Group type: EXPERIMENTAL
Intervention: RecImMir (hand laterality recognition, imagined movements, mirror movements)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ImRecIm (imagined movements, recognition, imagined movements)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RecMirRec (recognition, mirror movements, recognition)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hand laterality recognition (across all groups)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Imagined movements (following hand laterality recognition)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mirror movements (following imagined movements)
Number of subjects: 20
Study: 14508310

Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: A‐Line ARX index (AAI)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Predicted propofol effect‐site concentration (CePROP)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combined information from CePROP, CeREMI, and BIS or AAI
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Independent variables (BIS, AAI, CePROP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 45
Study: 10647274

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-pharmacological therapeutic modalities (radiofrequency catheter ablation, implantable antiarrhythmic devices)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic practice modifications
Number of subjects: 0
Study: 9084513

Group type: EXPERIMENTAL
Intervention: Manually controlled infusion of propofol (10‐12 mg/kg/h) and alfentanil (25 micrograms/kg/h) for 2 min, followed by atracurium (5 mg) and propofol (1‐1.5 mg/kg) as a bolus induction dose over 20 s.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thiamylal (4‐5 mg/kg) and fentanyl (2 micrograms/kg), atracurium (5 mg) and succinylcholine (1.5 mg/kg).
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thiamylal (4‐5 mg/kg) with additional sublingual nifedipine (1/2 capsule) 10 min prior to induction.
Number of subjects: 60
Study: 1879184

Group type: EXPERIMENTAL
Intervention: Intramuscular imipenem/cilastatin (500 or 750 mg every 12 hours)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intramuscular imipenem/cilastatin
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intramuscular imipenem/cilastatin (500 mg)
Number of subjects: 102
Study: 6978144

Group type: EXPERIMENTAL
Intervention: ICI 35, 868 (diisopropyl phenol in cremophor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 0
Study: 30672140

Group type: EXPERIMENTAL
Intervention: MDI-SIB (salbutamol and ipratropium by MDI with valved-holding chamber and mask)
Number of subjects: 103

Group type: COMPARATOR
Intervention: NEB-SIB (salbutamol and ipratropium by nebulizer)
Number of subjects: 103
Study: 27979818

Group type: EXPERIMENTAL
Intervention: Virtual reality exposure (n = 17)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: In vivo exposure (n = 22)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Waiting list (n = 20)
Number of subjects: 59
Study: 26021224

Group type: EXPERIMENTAL
Intervention: Immediate loading group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Repeated disconnection group
Number of subjects: 80
Study: 24300843

Group type: EXPERIMENTAL
Intervention: Half-dose sinogram-affirmed iterative reconstruction (HD-SAFIRE(2))
Number of subjects: 59

Group type: COMPARATOR
Intervention: Full-dose filtered back projection images (FD-FBP)
Number of subjects: 59
Study: 22074592

Group type: EXPERIMENTAL
Intervention: OHP (octenidine dihydrochloride/phenoxyethanol)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Ringer solution
Number of subjects: 126
Study: 19139424

Group type: EXPERIMENTAL
Intervention: Cisplatin-based concurrent chemoradiotherapy
Number of subjects: 644

Group type: COMPARATOR
Intervention: Mitomycin-based therapy
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Large tumor diameter (> 5 cm)
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Node-positive cancer
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 644
Study: 18077833

Group type: EXPERIMENTAL
Intervention: 8-session intervention based on motivational interviewing and cognitive-behavioral skills building
Number of subjects: 143

Group type: COMPARATOR
Intervention: Time- and content-equivalent educational condition
Number of subjects: 143
Study: 15528874

Group type: EXPERIMENTAL
Intervention: Combination treatment with losartan and trandolapril
Number of subjects: 92

Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 92

Group type: COMPARATOR
Intervention: Trandolapril
Number of subjects: 92
Study: 15463826

Group type: EXPERIMENTAL
Intervention: Induced sputum (IS)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Bronchoalveolar lavage (BAL)
Number of subjects: 31
Study: 9578230

Group type: EXPERIMENTAL
Intervention: Fittydent I
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fittydent II
Number of subjects: 32

Group type: COMPARATOR
Intervention: Protefix
Number of subjects: 32

Group type: COMPARATOR
Intervention: Seabond
Number of subjects: 32
Study: 7713830

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol and Placebo
Number of subjects: 12
Study: 2694142

Group type: EXPERIMENTAL
Intervention: Chlortenoxicam 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 411434

Group type: EXPERIMENTAL
Intervention: Low-dose insulin infusion at the rate of 6 units per hour
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose, intermittent subcutaneously administered insulin
Number of subjects: 0
Study: 31024649

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (USG)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Traditional blind palpation (TBP)
Number of subjects: 412
Study: 28586395

Group type: EXPERIMENTAL
Intervention: CTCs with strong HER2 staining
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: CTCs with negative HER2 staining
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Presence of HER2-positive CTCs
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Within-sample variation in HER2 status of CTCs
Number of subjects: 642

Group type: COMPARATOR
Intervention: Overall association of HER2-positive CTCs with tumor characteristics
Number of subjects: 642
Study: 26474517

Group type: EXPERIMENTAL
Intervention: Cediranib 20 mg orally once daily until disease progression
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cediranib
Number of subjects: 69
Study: 23815798

Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate administration prior to surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administration prior to surgery
Number of subjects: 0
Study: 21794173

Group type: EXPERIMENTAL
Intervention: Formal workshop in EBM literature searching skills
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 19341448

Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Single screening mammogram
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Repeated screening starting at age 50
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Screening at age 40
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Screening at age 50
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Screening at age 65
Number of subjects: 1000
Study: 16488958

Group type: EXPERIMENTAL
Intervention: Combined photodynamic therapy (PDT) with intravitreal triamcinolone (IVTA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: PDT monotherapy
Number of subjects: 48
Study: 15285023

Group type: EXPERIMENTAL
Intervention: DA-9601 180 mg
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: DA-9601 360 mg
Number of subjects: 512

Group type: COMPARATOR
Intervention: Cetraxate 600 mg
Number of subjects: 512
Study: 11127783

Group type: EXPERIMENTAL
Intervention: Complementary Medicine (CM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quality profiles comparison
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trials (RCTs)
Number of subjects: 0
Study: 9269642

Group type: EXPERIMENTAL
Intervention: RenaGel 1 g
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: RenaGel 2.5 g
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: RenaGel 5 g
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1586329

Group type: EXPERIMENTAL
Intervention: Intravenous Syntocinon
Number of subjects: 106

Group type: COMPARATOR
Intervention: Vaginal prostaglandin E2 pessaries
Number of subjects: 106
Study: 3517644

Group type: EXPERIMENTAL
Intervention: Tolazamide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Exogenous insulin
Number of subjects: 8
Study: 31597517

Group type: EXPERIMENTAL
Intervention: Trial volunteering
Number of subjects: 445

Group type: COMPARATOR
Intervention: Usual activities (Control)
Number of subjects: 445
Study: 29996542

Group type: EXPERIMENTAL
Intervention: Depression and anxiety prevention program 'Een Sprong Vooruit' (A Leap Forward)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 142
Study: 28031607

Group type: EXPERIMENTAL
Intervention: Flipped classroom with Poll Everywhere ARS
Number of subjects: 112
Study: 25281655

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 7141
Study: 22369603

Group type: EXPERIMENTAL
Intervention: Early external cephalic version at 34(0/7) to 35(6/7) weeks
Number of subjects: 1543

Group type: COMPARATOR
Intervention: Traditional timing of external cephalic version (greater than 37 weeks)
Number of subjects: 1543
Study: 20213585

Group type: EXPERIMENTAL
Intervention: Conventional regimen (13 cycles of 21+7 days)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Extended-cycle regimen (4 cycles of 84+7 days)
Number of subjects: 59
Study: 18373318

Group type: EXPERIMENTAL
Intervention: MCP treatment for 30 minutes during eight days
Number of subjects: 55

Group type: COMPARATOR
Intervention: No MCP treatment
Number of subjects: 55
Study: 16032749

Group type: EXPERIMENTAL
Intervention: Pegylated interferon plus ribavirin for 48 weeks
Number of subjects: 28
Study: 12151922

Group type: EXPERIMENTAL
Intervention: Standard hospital blankets (set point, 38 degrees C)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Commercial Bair Hugger blanket (control group, set point, 43 degrees C)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Standard hospital blankets
Number of subjects: 83

Group type: COMPARATOR
Intervention: Commercial Bair Hugger blanket
Number of subjects: 83
Study: 12024416

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 0

Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8655293

Group type: EXPERIMENTAL
Intervention: Pentoxifylline at a dose of 800 mg thrice daily
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control period (no treatment)
Number of subjects: 6
Study: 2140763

Group type: EXPERIMENTAL
Intervention: Phenylephrine HCl, 2.5%
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Thymoxamine HCl, 0.5%
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 7
Study: 435053

Group type: EXPERIMENTAL
Intervention: Albumin therapy
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control (no albumin therapy)
Number of subjects: 94
Study: 6312460

Group type: EXPERIMENTAL
Intervention: 1 g cefotiam twice daily for 10 days
Number of subjects: 35

Group type: COMPARATOR
Intervention: 1 g cephalothin 4-times daily for 10 days
Number of subjects: 35
Study: 30778742

Group type: EXPERIMENTAL
Intervention: Hospital-based work support intervention
Number of subjects: 106

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Receiving chemotherapy
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Low level of education
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Low work ability
Number of subjects: 106
Study: 30428909

Group type: EXPERIMENTAL
Intervention: Active Interpretation Bias Training (IBT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham training (Control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Active IBT
Number of subjects: 40
Study: 26475499

Group type: EXPERIMENTAL
Intervention: 0.12 % CHX + 0.05 % CPC (Perio-Aid® Treatment alcohol-free)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 0.03 % CHX + 0.05 % CPC new test formulation
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 24638976

Group type: EXPERIMENTAL
Intervention: Carum carvi extract (CAE) 30ml/day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 22179530

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 6206

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 6206
Study: 19537926

Group type: EXPERIMENTAL
Intervention: ECG body surface mapping (BSM) parameters in DM1 patients with AN
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Classic 12-lead ECG in DM1 patients
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: QT duration measured in 82 leads of thorax in DM1 patients
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: ECG BSM method
Number of subjects: 54

Group type: COMPARATOR
Intervention: ECG BSM parameters in DM1 patients without AN
Number of subjects: 54
Study: 18093490

Group type: EXPERIMENTAL
Intervention: Centralized telephone intervention by trained nurses
Number of subjects: 1518

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1518
Study: 16144891

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1744
Study: 11872656

Group type: EXPERIMENTAL
Intervention: Increased plasma amino acids (approximately 4.6 mmol/l)
Number of subjects: 7
Study: 9457223

Group type: EXPERIMENTAL
Intervention: 123I-labeled MIBG
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 125I-labeled MIBG
Number of subjects: 58
Study: 7871405

Group type: EXPERIMENTAL
Intervention: SAKK (HD-4)
Number of subjects: 113

Group type: COMPARATOR
Intervention: DHSG (HD-4)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: SAKK (HD-5)
Number of subjects: 113

Group type: COMPARATOR
Intervention: DHSG (HD-5)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: SAKK (HD-6)
Number of subjects: 113

Group type: COMPARATOR
Intervention: DHSG (HD-6)
Number of subjects: 113
Study: 2105049

Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 725

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 725
Study: 523673

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) administered via tablets, gel, and pessary bases
Number of subjects: 27
Study: 31124275

Group type: EXPERIMENTAL
Intervention: Lobectomy
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Stereotactic Ablative Radiotherapy (SABR)
Number of subjects: 10000
Study: 27681813

Group type: EXPERIMENTAL
Intervention: Intra-articular injections of hyaluronic acid 1.6% (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Syalox 300 Plus® (hyaluronic acid 300 mg + Boswellia serrata extract 100 mg) for 20 days followed by Syalox 150® (hyaluronic acid 150 mg) for another 20 days (group B)
Number of subjects: 60
Study: 25662958

Group type: EXPERIMENTAL
Intervention: OPCAB no-touch technique
Number of subjects: 400
Study: 23807157

Group type: EXPERIMENTAL
Intervention: Nurse-peer model
Number of subjects: 85

Group type: COMPARATOR
Intervention: Doctor-counselor model
Number of subjects: 85
Study: 21075370

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 8
Study: 19438847

Group type: EXPERIMENTAL
Intervention: High-dose furosemide (250-1000 mg/bid i.v.) plus hypertonic saline solutions (150 mL H(2)O with NaCl 1.4-4.6%)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: High-dose furosemide plus hypertonic saline solutions
Number of subjects: 84

Group type: COMPARATOR
Intervention: Repeated paracentesis and standard diuretic schedule
Number of subjects: 84
Study: 17974118

Group type: EXPERIMENTAL
Intervention: Immediate nonocclusal loading
Number of subjects: 52

Group type: COMPARATOR
Intervention: Early loading
Number of subjects: 52
Study: 15470832

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 1450 ppm F (n=218)
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 440 ppm F (n=226)
Number of subjects: 703

Group type: COMPARATOR
Intervention: Control group (n=259)
Number of subjects: 703
Study: 10886488

Group type: EXPERIMENTAL
Intervention: Desmopressin (10 microg intravenously)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Hexarelin (2 microgram kg‐1 intravenously)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg) suppression test
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Desmopressin and Hexarelin tests
Number of subjects: 23

Group type: COMPARATOR
Intervention: Hexarelin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Desmopressin
Number of subjects: 23
Study: 9291171

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8346832

Group type: EXPERIMENTAL
Intervention: Nitroprusside and diltiazem (bolus of 80 micrograms/kg with two consecutive infusions of 4.5 micrograms.kg‐1.min‐1 during the first 30 min and then 1.3 micrograms.kg‐1.min‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nitroprusside alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nitroprusside and diltiazem
Number of subjects: 20